Interstitial Cystitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Lipella Pharma, Abbott, Pfizer, MediciNova, Ironwood Pharma, Astellas

Posted on
by

Interstitial Cystitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Lipella Pharma, Abbott, Pfizer, MediciNova, Ironwood Pharma, Astellas
“Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the 7MM.

DelveInsight’s “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Interstitial Cystitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Cystitis Market Forecast

 

Some of the key facts of the Interstitial Cystitis Market Report: 

  • The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the Interstitial Cystitis Association, 3 to 8 million American women, or roughly 3 to 6 percent of all women, may have Interstitial Cystitis. In contrast, 1-4 million males also have Interstitial Cystitis
  • In the seven major markets, the total diagnosed prevalent population of Interstitial Cystitis patients was determined to be 2,425,036 in 2021, while in the United States, they were found to be 1,567,149
  • In 2021, it was determined that there were 5,952,356 Interstitial Cystitis patients in the US as a whole
  • Key Interstitial Cystitis Companies: Seikagaku Corporation, UCB Pharma, AbbVie, Integrative Therapeutics, Allergan, Lipella Pharma, Abbott, Pfizer, MediciNova, Ironwood Pharma, Astellas Pharma, Prevail Infoworks, Inc, Seikagaku Corporation, Urigen, Aquinox Pharma, and others
  • Key Interstitial Cystitis Therapies: SI-722, Certolizumab pegol/Cimzia, BOTOX, Peppermint oil, Onabotulinumtoxin A, LP-08, Adalimumab, PF-04383119, MN-001, IW-3300 rectal foam, ASP6294, VNX001, SI-722, URG101, AQX-1125, and others
  • Delvelnsight has also examined Interstitial Cystitis type-specific statistics. Based on this information, IC can be classified as either non-ulcerative or ulcerative. According to research, there were 1,410,434 instances of the non-ulcerative and 156,715 cases of the ulcerative form of Interstitial Cystitis in the United States in 2021.
  • The Interstitial Cystitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Cystitis pipeline products will significantly revolutionize the Interstitial Cystitis market dynamics.

 

Interstitial Cystitis Overview

Interstitial Cystitis (IC), commonly known as Painful Bladder Syndrome, is a chronic illness that causes pelvic pain occasionally as well as bladder pressure and pain. The pain can be mildly uncomfortable or extremely painful. Most people experience the need to urinate because the bladder, a hollow, muscular organ that collects urine, swells until it is full and then sends signals to the brain that it is time to urinate through the pelvic nerves.

 

Get a Free sample for the Interstitial Cystitis Market Report 

https://www.delveinsight.com/report-store/interstitial-cystitis-market-forecast

 

Interstitial Cystitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Interstitial Cystitis Epidemiology Segmentation:

The Interstitial Cystitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Interstitial Cystitis
  • Prevalent Cases of Interstitial Cystitis by severity
  • Gender-specific Prevalence of Interstitial Cystitis
  • Diagnosed Cases of Episodic and Chronic Interstitial Cystitis

 

Download the report to understand which factors are driving Interstitial Cystitis epidemiology trends @ Interstitial Cystitis Epidemiology Forecast

 

Interstitial Cystitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Cystitis market or expected to get launched during the study period. The analysis covers Interstitial Cystitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Interstitial Cystitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Interstitial Cystitis Therapies and Key Companies

  • SI-722: Seikagaku Corporation
  • Certolizumab pegol/Cimzia: UCB Pharma
  • BOTOX: AbbVie
  • Peppermint oil: Integrative Therapeutics
  • Onabotulinumtoxin A: Allergan
  • LP-08: Lipella Pharma
  • Adalimumab: Abbott
  • PF-04383119: Pfizer
  • MN-001: MediciNova
  • IW-3300 rectal foam: Ironwood Pharma
  • ASP6294: Astellas Pharma
  • VNX001: Prevail Infoworks, Inc
  • SI-722: Seikagaku Corporation
  • URG101: Urigen
  • AQX-1125: Aquinox Pharma

 

Discover more about therapies set to grab major Interstitial Cystitis market share @ Interstitial Cystitis Treatment Market

 

Interstitial Cystitis Market Strengths

  • The rise in the trend of awareness is surely a strength for the IC market. The prevalence has improved with years as back then IC was considered as a rare indication.
  • Research and development are ongoing, ranging from the preclinical stage to late stage to boon the market of IC in future.
  • Several associations such as Interstitial Cystitis Association, Urology Care Foundation, etc. are rigorously involved in providing clarity for IC paradigm

 

Interstitial Cystitis Market Opportunities

  • The market of IC lacks recently approved therapies from the designated authorities.
  • The exact aetiology and pathophysiology of IC have still not been validated.  
  • Lack of proper diagnosis or misdiagnosis in case of males is quite evident, resulting in weakness for the market.
  • There is a need for more epidemiology studies to study the occurrence of the IC thoroughly, especially in Japan

 

Scope of the Interstitial Cystitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Interstitial Cystitis Companies: Seikagaku Corporation, UCB Pharma, AbbVie, Integrative Therapeutics, Allergan, Lipella Pharma, Abbott, Pfizer, MediciNova, Ironwood Pharma, Astellas Pharma, Prevail Infoworks, Inc, Seikagaku Corporation, Urigen, Aquinox Pharma, and others
  • Key Interstitial Cystitis Therapies: SI-722, Certolizumab pegol/Cimzia, BOTOX, Peppermint oil, Onabotulinumtoxin A, LP-08, Adalimumab, PF-04383119, MN-001, IW-3300 rectal foam, ASP6294, VNX001, SI-722, URG101, AQX-1125, and others
  • Interstitial Cystitis Therapeutic Assessment: Interstitial Cystitis current marketed and Interstitial Cystitis emerging therapies
  • Interstitial Cystitis Market Dynamics: Interstitial Cystitis market drivers and Interstitial Cystitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Interstitial Cystitis Unmet Needs, KOL’s views, Analyst’s views, Interstitial Cystitis Market Access and Reimbursement 

 

To know more about Interstitial Cystitis companies working in the treatment market, visit @ Interstitial Cystitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Interstitial Cystitis Market Report Introduction

2. Executive Summary for Interstitial Cystitis

3. SWOT analysis of Interstitial Cystitis

4. Interstitial Cystitis Patient Share (%) Overview at a Glance

5. Interstitial Cystitis Market Overview at a Glance

6. Interstitial Cystitis Disease Background and Overview

7. Interstitial Cystitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Cystitis 

9. Interstitial Cystitis Current Treatment and Medical Practices

10. Interstitial Cystitis Unmet Needs

11. Interstitial Cystitis Emerging Therapies

12. Interstitial Cystitis Market Outlook

13. Country-Wise Interstitial Cystitis Market Analysis (2019–2032)

14. Interstitial Cystitis Market Access and Reimbursement of Therapies

15. Interstitial Cystitis Market Drivers

16. Interstitial Cystitis Market Barriers

17.  Interstitial Cystitis Appendix

18. Interstitial Cystitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services